Effects of acetaminophen and ibuprofen monotherapy in febrile children: a meta-analysis of randomized controlled trials

Ning Kuo1, Nien-Yin Su1, Sen-Kuang Hou1,2, Yi-No Kang1,3,4,5,6

1Department of Emergency Medicine, Taipei Medical University Hospital, Taiwan
2Department of Emergency Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taiwan
3Evidence-Based Medicine Center, Wan Fang Hospital, Taipei Medical University, Taiwan
4Institute of Health Policy and Management, College of Public Health, National Taiwan University, Taiwan
5Cochrane Taiwan, Taipei Medical University, Taipei, Taiwan
6Department of Health Care Management, College of Health Technology, National Taipei University of Nursing Health Sciences, Taipei, Taiwan

Submitted: 16 April 2021; Accepted: 4 August 2021
Online publication: 22 August 2021

Arch Med Sci 2022; 18 (4): 965–981
DOI: https://doi.org/10.5114/aoms/140875
Copyright © 2022 Termedia & Banach

Abstract

Introduction: When a child presents with fever in the clinical encounter, parents are usually concerned about alleviating the fever. However, the indications for selecting an appropriate drug from the most commonly used antipyretic drugs, acetaminophen and ibuprofen, remain unclear. The purpose of this study was to assess the efficacy and safety of acetaminophen and ibuprofen in febrile children through a systematic review with meta-analysis of randomized controlled trials (RCTs).

Material and methods: Cochrane, Embase, and PubMed databases were searched for the relevant RCTs. Two authors individually extracted information on trial design, demography, rate of fever resolution, body temperature, and overall adverse events. Data were pooled mainly using a random-effects model; however, because of some sparse data, Peto odds ratios (PORs) were used for outcomes of fever resolution and adverse event. 95% confidence intervals (CIs) were also presented.

Results: In total, 26 RCTs (n = 4137) fulfilled eligibility criteria. Pooled estimates demonstrated that acetaminophen led to significantly lower fever resolution rates than ibuprofen did (POR = 0.91, 95% CI: 0.84–0.98; I² = 0%) in the subgroup of trials with a mean age of < 2 years. However, the treatment–time interaction model for body temperature demonstrated that the fever resolution effect was mainly from the time factor based on the available data (effect size = −0.20; 95% CI: −0.30 to −0.11; I² = 6.9%). Acetaminophen demonstrated lower overall adverse event rates than ibuprofen (POR = 0.71; 95% CI: 0.58–0.87; I² = 0%).

Conclusions: The effects of ibuprofen are similar to acetaminophen even in children with mean age of approximately 5 years. Nevertheless, acetaminophen is safer than ibuprofen, particularly in children approximately 5 years old.

Key words: fever resolution, fever, pediatric, paracetamol, ibuprofen.

Introduction

Children experience fever more frequently than adults. Fever is a crucial immune response of the body that helps us eliminate invad-
ing pathogens [1], and is a common symptom in various pediatric diseases, particularly infectious diseases [2]. In general, when febrile children present to a clinic, physicians focus on determining and treating the underlying cause of the pyrexia, whereas parents are more concerned about alleviating the fever itself. Fever is also a common reason for visiting physicians. This phenomenon is called “fever phobia” [3]. The role of antipyretic medication is to ease the child’s discomfort caused by fever and prevent dehydration [4]. The most commonly recommended antipyretic drugs are acetaminophen and ibuprofen [5]. Acetaminophen has a longer history, starting in the 1950s when it replaced aspirin to prevent Reye’s syndrome; currently, its labeled dose is 10–15 mg/kg every 4 h in children aged > 3 months [6]. Ibuprofen, approved for use in febrile children in 1989, is a common over-the-counter medication [7]; currently, its labeled dose is 5–10 mg/kg every 6–8 h in children aged > 6 months.

Ibuprofen is conventionally considered more effective than acetaminophen in the treatment of fever [8], because it has a longer duration of action than does acetaminophen (6–8 vs. 4 h). Nevertheless, acetaminophen demonstrates a low adverse effect risk [9, 10]. A series of studies have assessed acetaminophen and ibuprofen prescription in the pediatric population. However, to our knowledge, only two systematic reviews have discussed monotherapy of the two medications for febrile children, and both syntheses mixed febrile and non-febrile children [8, 11]. The earlier synthesis, in 2004, only analyzed 10 of the 17 included randomized controlled trials (RCTs) for febrile children, while the other RCTs did not focus on febrile children [8]. Since the meta-analysis also included RCTs regarding pain management in children, the safety of the two medications in the synthesis mixed febrile and non-febrile children. The other meta-analysis published in 2020 had a similar situation, and focused on children under 2 years old [11]. Moreover, six related RCTs on this topic had been published before the previous systematic reviews [12–17]. The most effective clinical practice for using these two antipyretic medications remains unclear [18].

To improve the confidence and understanding in using the two antipyretic medications, updated evidence including all relevant RCTs is required. The study aimed to assess the efficacy and safety of acetaminophen and ibuprofen in febrile children, and the elements of our research question in the PICO form are as follows:

- patients/population/problem: children with fever,
- intervention: acetaminophen,
- comparison: ibuprofen,
- outcome: fever resolution rate, body temperature, and complication rate.

Material and methods

To appropriately answer our research question, we performed the study adhering to the guidance in the Cochrane Handbook for Systematic Reviews of Interventions [19]. We then referred to the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analyses to report our study, including eligibility criteria, data source, evidence selection, data extraction, quality evaluation, data pooling, and result reporting [20]. The protocol for this study has been published on PROSPERO (CRD42020150731).

Eligibility criteria

Based on the PICO of this study, the authors defined primary eligibility criteria for evidence selection before the search. The inclusion criteria were as follows: (a) patients with fever, (b) population sample represented by a pediatric group aged < 18 years, (c) therapy comprised at least one arm of acetaminophen and the other arm of ibuprofen for antipyretic treatment, and (d) the study had to be an RCT since RCT is a better study design for evidence regarding effects of intervention according to the recommendation of Cochrane handbook [19]. We did not exclude evidence according to sex, disease, dosage, and administration route.

Data source and evidence selection

Potential studies were mainly identified from the Cochrane Database of Systematic Reviews (including the Cochrane Central Register of Controlled Trials (CENTRAL)), Embase, and PubMed databases by using relevant keywords about four core elements using the terms fever, pediatric, acetaminophen, and ibuprofen. The relevant keywords consisted of free text and medical subject headings. The Boolean operator “OR” was used to combine synonyms of each core element, and the operator “AND” was applied to connect the four search parts. References were screened using the primary search strategy without any filters for restricting study design, publication date, language, or age (Appendix 1). In addition, Google Scholar was also searched; however, it had no advanced search function. Reference lists of relevant systematic reviews and RCTs were also screened for potential eligible evidence. A final search was performed for potential evidence before March 2021.

To identify eligible evidence, two authors (N.G. and N.Y.S.) independently screened titles and abstracts to eliminate irrelevant references. Subsequently, the full text of the remaining references was retrieved and carefully reviewed. The two authors excluded references according to the eligibility criteria mentioned earlier, and they further eliminated gray literature without details about
study design, medication information, baseline characteristics, or outcomes during the full-text review step. After the two-step screening process, the two authors simultaneously checked the eligible evidence for the present study. If there was any disagreement related to selected evidence, an experienced researcher was consulted, who also made all final decisions about the included evidence.

Data extraction and quality evaluation

All eligible evidence for this study was further reviewed for data extraction and quality assessment. The two authors individually extracted studies by publication year, information of trial designs, characteristics of samples, diagnostic measures of fever, the definition of fever, types of intervention, the termination point of the study, and outcome measures. Types of intervention were different dosages and administration routes of acetaminophen and ibuprofen. The primary outcome measures were nonfebrile count; mean body temperature at baseline and 1, 2, 4, and 6 h after administration of antipyretics based on the pharmacokinetics research [21, 22]; and adverse effects classified by the system (gastrointestinal, respiratory, neurologic, dermatologic, hematologic, ear, nose and throat, and hypothermia). They double-checked data mutually before analysis. Then, the two authors and an experienced researcher had a meeting to resolve disagreements between them through triple-checking and discussion.

Quality evaluation was based on data extraction. To assess the risk of bias, the Cochrane risk-of-bias tool 2 (RoB 2), first released in the Cochrane Handbook for Systematic Reviews of Interventions in 2016 and updated in 2019, was used [23, 24]. Because the RoB 2 adopts an outcome-oriented approach, the two authors evaluated bias from the randomization process, deviations from intended interventions, missing outcome data, measurement of outcome, and selection of the reported result in each trial of every outcome.

Data synthesis and analysis

Trial characteristics and patient demographic information were synthesized qualitatively, and relevant outcomes were combined quantitatively. Head-to-head meta-analysis in a random-effects model was performed for quantitative analysis. Because fever resolution and adverse event rates were dichotomous variables, their events and non-events with each medication were used for obtaining the risk ratios and 95% confidence intervals (CIs). The Peto odds ratio (POR) was also estimated when any sparse cell existed in the fever resolution or adverse event rates. Interpretation of pooled estimates using sparse data was mainly based on POR for statistical robustness [19]. Weighted mean differences (WMDs) between acetaminophen monotherapy and ibuprofen monotherapy were estimated based on means, standard deviations, and sample sizes of each variable for each medicine.

To evaluate the quality of the pooled data, small study effects and heterogeneity were tested. The funnel plot and Egger’s test were performed to detect small study effects within pooled fever resolution rates, the difference in body temperatures, and adverse event rates. Because body temperatures were reported for multiple time points, a treatment–time interaction model was assessed [25]. Heterogeneity among the included trials was detected using $p$ statistics. If $p \geq 50\%$ or $p$-value $< 0.10$ for any outcome, the pooled result was considered highly heterogeneous. Subgroups of measuring time and age range were further analyzed for statistical and clinical heterogeneity. All analyses were performed using STATA for Microsoft Windows (version 14).

After quantitative synthesis of fever resolution, body temperature, and adverse event rates, the Grading of Recommendation, Assessment, Development, and Evaluations (GRADE) was further applied to the overall judgment of each finding for clinical practice [26]. Results of the GRADE evaluation mainly consist of certainty of the evidence, relative effects, and comments. There are four levels of certainty of the evidence: Very Low ($\oplus\oplus\oplus\oplus$), Low ($\oplus\oplus\oplus$), Moderate ($\oplus\oplus\circ$), and High ($\oplus\circ\circ\circ$).

Results

Our search yielded a total of 559 articles from the Cochrane (k = 154), Embase (k = 144), and PubMed (k = 261) databases. Four more articles were identified from reference lists of relevant systematic reviews and Google Scholar. Of these, 529 were excluded because they were duplicat-ed (k = 183), were irrelevant (k = 88), did not include children with fever (k = 67), did not compare acetaminophen and ibuprofen monotherapies (k = 131), were not RCTs (k = 51), were abstracts without details (k = 5), and were other documents (k = 4). Of the remaining 34 articles, we further excluded 9 because they did not compare acetaminophen and ibuprofen monotherapies. Finally, 26 RCTs were included in this systematic review and meta-analysis [7, 12–17, 27–45]. The flow of article selection is illustrated in Figure 1.

Characteristics and quality of included studies

The 26 included RCTs recruited 4137 children with fever from Africa, the Americas, Asia, and Europe. These trials were published between 1989 and 2020. Based on available data, the mean age ranged from 1.5 to 6.23 years. Most trials report-
ed that baseline body temperature was > 38.5°C, except in a trial by Wilson with a temperature of approximately 37.5°C in each group and three trials without baseline body temperature [15, 36, 37, 44]. Eight trials clearly declared that children receiving antibiotics were excluded [13, 29–31, 34, 38, 40, 41]. Table I lists demographic information, and Appendix 2 presents the quality of the included RCTs according to the outcome of interest.

Fever resolution rate and body temperature

Data on fever resolution rates could be derived from 18 RCTs (n = 2734). The pooled estimate of fever resolution rates demonstrated that both acetaminophen (931/1329) and ibuprofen (1042/1405) monotherapies led to similar fever resolution rates (Figure 2), and the POR of fever resolution was 0.99 (95% CI: 0.97 to 1.001). However, the pooled estimate was highly heterogeneous ($I^2 = 72.9%$), and high heterogeneity existed between subgroups ($I^2 = 52.6%, p < 0.10$). Egger’s test did not detect small study effects (coefficient = −0.27; $p > 0.05$; Figure 3). In the subgroup of trials with a mean age of < 2 years, notably, acetaminophen monotherapy demonstrated a significantly lower fever resolution rate than did ibuprofen monotherapy (POR = 0.91, 95% CI: 0.84 to 0.98; $I^2 = 0$%). No significant difference in fever resolution rates between the two medications could be observed in the subgroups of trials with a mean age between 2 to 5 years old and above 5 years old.

In total, 21 RCTs (n = 3569) reported body temperature data. The data for children’s body temperature at baseline (22 RCTs) and 1 (7 RCTs, n = 1069), 2 (7 RCTs, n = 1053), 4 (6 RCTs, n = 783), and 6 (5 RCTs, n = 606) h after medication administration were available (Appendix 3). Pooled estimates demonstrated no significant difference in body temperature between acetaminophen and ibuprofen at baseline and 1 and 2 h after intervention, whereas the pooled estimates were highly heterogeneous. Furthermore, compared with ibuprofen, acetaminophen demonstrated higher body temperatures 4 (WMD = 0.27; 95% CI: 0.08 to 0.45) and 6 (WMD = 0.23; 95% CI: 0.02 to 0.43) hours after administration. The treatment–time interaction model, however, demonstrated that the fever resolution effect was mainly from the time factor based on the available data (effect size = −0.20; 95% CI: −0.30 to −0.11; $I^2 = 6.9%$). No significant effect from acetaminophen monotherapy or treatment–time interaction could be observed (Appendix 4).

Safety

Data on adverse event rates were derived from 18 RCTs (n = 3286). A pooled estimate demonstrated that neither acetaminophen nor ibuprofen monotherapy demonstrated a significant difference in overall adverse event rates (POR = 0.97; 95% CI: 0.93 to 1.01; Figure 4), although high heterogeneity was observed in the pooled estimate ($I^2 = 67.1%$) and between subgroups ($I^2 = 78.4%$, $p < 0.05$). The pooled estimate of overall adverse event rates might not be considerably biased by small study effects (coefficient = −0.20; $p > 0.05$). Subgroup analysis demonstrated no significant differences in overall adverse event rates between acetaminophen and ibuprofen monotherapies in trials with a mean age of < 2 years old as well as mean age between 2 and 5 years old. Significant findings were observed only in trials with a mean age of > 5 years, where acetaminophen monotherapy demonstrated lower overall adverse event rates than ibuprofen monotherapy (POR = 0.71; 95% CI: 0.58 to 0.87; $I^2 = 0$%). Table II shows the summary of findings and certainty of evidence regarding the effects of acetaminophen and ibuprofen on afebrile rate and overall complication.
## Table 1. Characteristics of the included randomized controlled trials

| Author          | Area            | Treatment               | Frequency | Form | Sex (M/F) | Age  |
|-----------------|-----------------|-------------------------|-----------|------|-----------|------|
| Alaje et al.    | Africa          | Acetaminophen 15 mg     | Single dose | PO   | 35/35     | 2.23 |
|                 |                 | Ibuprofen 10 mg         | Single dose | PO   | 35/35     | 2.22 |
| Autret et al.   | Europe          | Acetaminophen 10 mg     | Q6H       | PO   | 43/34     | 1.9  |
|                 |                 | Ibuprofen 7.5 mg        | Q6H       | PO   | 47/30     | 2.06 |
| Autret et al.   | Europe          | Acetaminophen 10 mg     | Q6H       | PO   | NR        | NR   |
|                 |                 | Ibuprofen 7.5 mg        | Q6H       | PO   | NR        | NR   |
| Autret et al.   | Europe          | Acetaminophen 15 mg     | Q6H       | PO   | 78/72     | 3.71 |
|                 |                 | Ibuprofen 10 mg         | Q6H       | PO   | 73/78     | 3.84 |
| Celebi et al.   | Middle East     | Acetaminophen 15 mg     | NR        | PO   | 59/53     | 3.96 |
|                 |                 | Ibuprofen 10 mg         |           | PO   | 43/41     | 3.77 |
| Choi et al.     | Asia            | Propacetamol 15/30mg    | Single dose | IV   | 63/62     | 3    |
|                 |                 | Ibuprofen 6 mg          | Single dose | PO   | 70/68     | 3    |
| Erlewyn et al.  | Europe          | Acetaminophen 15 mg     | Single dose | PO   | NR        | 1.5  |
|                 |                 | Ibuprofen 5mg           | Single dose | PO   | 1.5       |
| Figueras et al. | Europe          | Acetaminophen 10.65 mg  | Single dose | PO   | 60/39     | 3.78 |
|                 |                 | Ibuprofen 6.67 mg       | Single dose | PO   | 52/48     | 3.48 |
| Hay et al.      | Europe          | Acetaminophen 15 mg     | Q4H       | PO   | 26/26     | 2.39 |
|                 |                 | Ibuprofen 10 mg         | Q6H       | PO   | 37/15     | 2.34 |
| Jayawardena et al. | North America | Acetaminophen 10–15 mg | Single dose | PO   | 71/85     | 4.85 |
|                 |                 | Ibuprofen 7.5 mg        | Single dose | PO   | 73/90     | 4.36 |
| Kauffman et al. | North America   | Acetaminophen 10 mg     | Single dose | PO   | 1/7       | 5.3  |
|                 |                 | Ibuprofen 7.5/10 mg     | Single dose | PO   | 6/14      | 6.08 |
| Kelley et al.   | North America   | Acetaminophen 11.6 mg   | Single dose | PO   | 6/10      | 5.9  |
|                 |                 | Ibuprofen 6 mg          | Single dose | PO   | 9/8       | 5.8  |
| Khalil et al.   | North America   | Acetaminophen 10 mg     | Q4H       | PO/R | 26/27     | 6    |
|                 |                 | Ibuprofen 10 mg         | Q4H       | IV   | 27/20     | 7    |
| Luo et al.      | Europe          | Acetaminophen 10 mg     | Q6H       | PO   | 93/63     | 2.65 |
|                 |                 | Ibuprofen 10 mg         | Q6H       | PO   | 91/66     | 2.44 |
| McIntyre et al. | Europe          | Acetaminophen 12.5 mg   | Q6H       | PO   | 47/27     | 1.6  |
|                 |                 | Ibuprofen 5 mg          | Q6H       | PO   | 42/34     | 1.8  |
| Nwanyanwu et al.| Nigeria         | Acetaminophen 12.5 mg   | Q6H       | PO   | NR        | NR   |
|                 |                 | Ibuprofen 5 mg          | Q6H       | PO   | NR        | NR   |
| Sarrell et al.  | Middle East     | Acetaminophen 12.5 mg   | Q6H       | PO   | 71/83     | 1.55 |
|                 |                 | Ibuprofen 5 mg          | Q8H       | PO   | 73/82     | 1.63 |
| Seyfhashemi et al. | Middle East | Acetaminophen 15 mg     | Q4H       | PO   | NR        | NR   |
|                 |                 | Ibuprofen 10 mg         | Q6H       | PO   | NR        | NR   |
| Ulukol et al.   | Middle East     | Acetaminophen 10 mg     | Q8H       | PO   | 15/15     | 5.6  |
|                 |                 | Ibuprofen 10 mg         | Q8H       | PO   | 20/10     | 4.7  |
| Van Esch et al. | Europe          | Acetaminophen 10 mg     | Q6H       | PO   | 19/17     | 2.06 |
|                 |                 | Ibuprofen 5 mg          | Q6H       | PO   | 24/10     | 2.08 |
| Vauzelle et al. | Europe          | Acetaminophen 9.8 mg    | Single dose | PO   | 29/27     | 4.2  |
|                 |                 | Ibuprofen 10.3 mg       | Single dose | PO   | 30/30     | 4    |
| Vyas et al.     | Asia            | Acetaminophen 15 mg     | Single dose | PO   | 17/13     | 5.56 |
|                 |                 | Ibuprofen 10 mg         | Single dose | PO   | 16/16     | 6.23 |
| Walson et al.   | North America   | Acetaminophen 10 mg     | Single dose | PO   | NR        | Overall |
|                 |                 | Ibuprofen 5/10 mg       | Single dose | PO   | 5.8      |
| Walson et al.   | North America   | Acetaminophen 15 mg     | Q6H       | PO   | 7/9       | 5.2  |
|                 |                 | Ibuprofen 2.5/5/10 mg   | Q6H       | PO   | 15/15     | 5.35 |
| Wilson et al.   | North America   | Acetaminophen 12.5 mg   | Single dose | PO   | NR        | Overall |
|                 |                 | Ibuprofen 5/10 mg       | Single dose | PO   | 3.36     |
| Wong et al.     | South America   | Acetaminophen 12 mg     | Single dose | PO   | 110/100   | 2.58 |
|                 |                 | Ibuprofen 5/10 mg       | Single dose | PO   | 118/91    | 2.42 |

M/F – male/female, NR – no report, PO – per os, Q4H – per 4 h, Q6H – per 6 h.
Table 2. Forest plot for fever resolution rate between acetaminophen and ibuprofen monotherapies

| Subgroup/study          | RR (95% CI)          | Weight (% D + L) |
|-------------------------|----------------------|------------------|
| Mean age: < 2 years old |                      |                  |
| Seyfhashemi et al. 2007 | 0.81 (0.68, 0.96)    | 18.36            |
| McIntyre et al. 1996    | 0.93 (0.85, 1.02)    | 63.98            |
| Autret et al. 1997      | 0.93 (0.66, 1.30)    | 4.69             |
| Autret et al. 1994      | 0.95 (0.77, 1.16)    | 12.97            |
| D + L Subtotal (I² = 0.0%, p = 0.535) | 0.91 (0.84, 0.98) | 100.00           |
| Peto Subtotal           | 0.91 (0.84, 0.98)    |                  |
| Mean age: 2–5 years old |                      |                  |
| Van Esch et al. 1995    | 0.76 (0.59, 0.98)    | 7.30             |
| Wong et al. 2001        | 0.87 (0.77, 0.98)    | 13.70            |
| Wilson et al. 1991      | 0.90 (0.76, 1.07)    | 10.94            |
| Figueras et al. 2002    | 0.94 (0.67, 1.31)    | 5.02             |
| Alaje et al. 2020       | 0.95 (0.83, 1.09)    | 13.19            |
| Vauzelle et al. 1997    | 0.98 (0.91, 1.06)    | 16.27            |
| Luo et al. 2017         | 0.99 (0.98, 1.01)    | 18.59            |
| Hay et al. 2008         | 1.02 (0.88, 1.18)    | 12.39            |
| Choi et al. 2018        | 1.25 (0.75, 2.07)    | 2.60             |
| Nwanyanwu et al. 1999   | (Excluded)           |                  |
| D + L Subtotal (I² = 79.1%, p < 0.001) | 0.94 (0.87, 1.03) | 100.00           |
| Peto Subtotal           | 0.99 (0.97, 1.00)    |                  |
| Mean age: > 5 years old |                      |                  |
| Watson et al. 1989      | 0.82 (0.67, 1.00)    | 20.82            |
| Khalil et al. 2017      | 0.82 (0.69, 0.98)    | 22.01            |
| Watson et al. 1992      | 1.13 (0.92, 1.38)    | 20.66            |
| Vyasa et al. 2014       | 1.14 (0.99, 1.31)    | 23.60            |
| Ulukol et al. 1999      | 1.50 (1.03, 2.19)    | 12.91            |
| D + L Subtotal (I² = 76.8%, p = 0.002) | 1.02 (0.85, 1.24) | 100.00           |
| Peto Subtotal           | 1.01 (0.92, 1.10)    |                  |
| D + L Overall (I² = 72.9%, p < 0.001) | 0.95 (0.89, 1.01) |                  |
| Peto Overall            | 0.99 (0.97, 1.00)    |                  |

Note: Weights are from random effects analysis.

Discussion

On the basis of the available evidence, the present pooled results revealed that children in the acetaminophen group displayed temperatures about 0.2°C higher than those in the ibuprofen group, which indicated that the efficacy of ibuprofen was slightly better than that of acetaminophen. However, this result might not be significant in clinical settings. By contrast, about 29% lower risk was observed in the acetaminophen group than in the ibuprofen group regarding overall adverse event rates in the subgroup of mean age of > 5 years. The safety finding may raise concerns in clinical practice.

The minimum age for using acetaminophen ranged from 0 months [46–48] to 2 months [49] and 3 months [6, 50]; however, the NICE guidelines provide no suggestions for age [51]. The dosage of acetaminophen varied as follows: a single dose of 10–15 or > 15 mg/kg, intervals between doses of 4, 4–6, or 6 h, and maximum daily dosage of 60–90 mg/kg/day.

Some studies have recommended 2 months [49], 3 months [50], and 6 months [6, 48] as the minimum age for ibuprofen administration, whereas no such suggestions are covered in other studies [46, 47, 51]. The dosage of ibuprofen is divergent in a single administration (5–10 or 10 mg/kg/dose), intervals between doses (6, 6–8 h), and a maximum daily dosage of 40 mg for all guidelines, except for the Italian Pediatric Society Guidelines, which allow the dose of up to
Figure 3. Small study tests using funnel plot for fever resolution rate (A), Egger’s test for fever resolution rate (B), funnel plot for overall adverse event rate (C), and Egger’s test for overall adverse event rate (D).

30 mg [47]. In the guidelines we discussed, all used either acetaminophen or ibuprofen in children with fever who appeared distressed. The choice of these two recommended antipyretics is made according to the child’s age, weight, and other characteristics. In some situations, ibuprofen administration should be cautious. Ibuprofen may worsen asthma symptoms and should be prescribed cautiously [50]. In children with dehydration, ibuprofen use is contraindicated by the Italian Pediatric Society Guidelines but recommended with caution by the American Academy of Pediatrics [6] and guidelines in South Africa and South Australia [46, 50]. In the case of varicella, using ibuprofen is contraindicated by the Italian Pediatric Society Guidelines but recommended with caution by the American Academy of Pediatrics and guidelines in South Africa [6, 47, 50]. Although part of our analysis supports these guidelines, some differences were noted.

According to our analysis, in children with a mean age < 2 years, ibuprofen was more effective than acetaminophen. The same result was observed in children with a mean age between 2 and 5 years. Moreover, the side effects compared between ibuprofen and acetaminophen demonstrated no obvious difference in groups with mean ages of under 2 years. Although ibuprofen may be preferred for a rapid antipyretic effect, more studies are required to establish its safety. In studies with a mean age of > 5 years, no obvious difference in effectiveness was observed between acetaminophen and ibuprofen. Furthermore, acetaminophen monotherapy demonstrated fewer side effects than did ibuprofen monotherapy. As per our observations, no differences were observed in the antipyretic effects between ibuprofen monotherapy and acetaminophen monotherapy with older age.

In total, 1,329 people comprised the acetaminophen group with available fever resolution data, and the acetaminophen group was administered dosages of 9.8, 10, 12.5, and ≥ 15 mg/kg (up to 30 mg/kg). We did not observe a notable increment in antipyretic effects with increasing dosage. Out of twenty-four included studies with the oral route of medication, there was only one study with the intravenous route of acetaminophen and one study with the rectal or oral route of acetaminophen and intravenous route of ibuprofen. There was a difference in pharmacokinetics when the administration route was different, which might have led to the variation of time-related antipyretic efficacy [52, 53]. Nevertheless, there was no outcome difference when these two studies with different routes of medication were weeded out from the analysis. Regarding the adverse effects of acetaminophen, our analysis demonstrated a trend wherein the risk of an adverse event increased, similar to that of the ibuprofen group, with an in-
Ning Kuo, Nien-Yin Su, Sen-Kuang Hou, Yi-No Kang

Arch Med Sci
4, 1st July / 2022

Figure 4. Forest plot for overall adverse event rate between acetaminophen and ibuprofen monotherapies

| Subgroup/study | RR (95% CI) | Weight (%) |
|----------------|-------------|------------|
| **Mean age: < 2 years old** | | |
| Autret et al. 1997 | 0.11 (0.01, 0.86) | 41.85 |
| McIntyre et al. 1996 | 1.16 (0.64, 2.09) | 58.15 |
| D + L Subtotal ($I^2 = 80.7\%, p = 0.023$) | 0.43 (0.04, 4.77) | 100.00 |
| Peto Subtotal | 0.96 (0.55, 1.70) | |
| **Mean age: 2–5 years old** | | |
| Wilson et al. 1991 | 0.34 (0.02, 7.02) | 0.02 |
| Celebi et al. 2009 | 0.38 (0.12, 1.20) | 0.14 |
| Alaje et al. 2020 | 0.63 (0.31, 1.28) | 0.37 |
| Figueras et al. 2002 | 0.66 (0.24, 1.78) | 0.19 |
| Wong et al. 2001 | 0.90 (0.50, 1.62) | 0.54 |
| Luo et al. 2017 | 0.99 (0.94, 1.03) | 97.37 |
| Autret et al. 2007 | 1.01 (0.39, 2.61) | 0.21 |
| Jayawardena et al. 2017 | 1.17 (0.55, 2.49) | 0.33 |
| Hay et al. 2008 | 1.18 (0.70, 1.98) | 0.70 |
| Van Esch et al. 1995 | 1.18 (0.35, 4.03) | 0.12 |
| Vauzelle et al. 1997 | 5.35 (0.26, 109.08) | 0.02 |
| D + L Subtotal ($I^2 = 0.0\%, p = 0.459$) | 0.99 (0.94, 1.03) | 100.00 |
| Peto Subtotal | 0.99 (0.94, 1.03) | |
| **Mean age: > 5 years old** | | |
| Watson et al. 1992 | 0.58 (0.03, 11.42) | 0.47 |
| Choi et al. 2018 | 0.65 (0.45, 0.94) | 30.61 |
| Khalil et al. 2017 | 0.65 (0.38, 1.12) | 14.29 |
| Vyas et al. 2014 | 0.71 (0.13, 3.97) | 1.43 |
| Watson et al. 1989 | 0.76 (0.58, 1.01) | 53.19 |
| D + L Subtotal ($I^2 = 0.0\%, p = 0.950$) | 0.71 (0.58, 0.87) | 100.00 |
| Peto Subtotal | 0.71 (0.58, 0.87) | |
| D + L Overall ($I^2 = 67.1\%, p < 0.001$) | 0.82 (0.64, 1.05) | |
| Peto overall | 0.97 (0.93, 1.01) | |

Note: Weights are from random effects analysis.

Increasing acetaminophen dose. Multisystemic adverse effects caused by acetaminophen use have been mentioned in other studies including gastrointestinal (vomiting), dermatologic (skin rash), metabolic (hyponatremia), hematologic (pancytopenia), and hepatic (elevation of serum alkaline phosphatase and bilirubin). The incidence of adverse events mentioned earlier was still low, and few cases of catastrophic clinical outcomes caused by these adverse effects were reported [54, 55]. Therefore, we recommend a dosage of 10 mg/kg acetaminophen that exerts the maximum antipyretic effects with a relatively low adverse event risk. Compared with the acetaminophen group, a higher proportion of patients in the ibuprofen group developed adverse effects, especially symptoms of the gastrointestinal system. In the included studies, the gastrointestinal symptoms most documented were nausea, vomiting, abdominal pain, and diarrhea. By contrast, few studies have reported overt gastrointestinal bleeding symptoms, such as melena, hematemesis, and hematochezia, which indicated that there were not more significant events of gastrointestinal bleeding or mortality despite the higher risk of adverse effects in the ibuprofen group than in the acetaminophen group. Although the safety of ibuprofen raised little concern, subtle adverse effects attributed to medications still bother and affect the quality of life of the caregivers. Parents, who are not professionals of medicine or related fields, are extremely anxious about disease progression and adverse events caused by diseases in their children, even incurable illnesses such as the common cold [56]. Subtle adverse effects could conceivably worsen the parents’ quality of life.
Effects of acetaminophen and ibuprofen monotherapy in febrile children: a meta-analysis of randomized controlled trials

Table II. Summary of findings

| No. of participants (studies) | Certainty of the evidence (GRADE) | Relative effects (95% CI) | Comments |
|-------------------------------|-----------------------------------|--------------------------|----------|
| Afebrile rate (mean age: < 2 years) | 620 (4 RCTs) | LOW | POR 0.91 (0.84 to 0.98) | Acetaminophen may slightly decrease afebrile rate |
| Afebrile rate (mean age: 2–5 years) | 1566 (9 RCTs) | LOW | POR 0.99 (0.97 to 1.01) | Acetaminophen does not decrease afebrile rate |
| Afebrile rate (mean age: > 5 years) | 353 (5 RCTs) | VERY LOW | POR 1.01 (0.92 to 1.10) | Acetaminophen does not increase afebrile rate |
| Overall complication (mean age: < 2 years) | 382 (2 RCTs) | LOW | POR 0.96 (0.55 to 1.70) | Acetaminophen does not reduce overall complication rate |
| Overall complication (mean age: 2–5 years) | 2323 (11 RCTs) | MODERATE | POR 0.99 (0.94 to 1.03) | Acetaminophen does not reduce overall complication rate |
| Overall complication (mean age: > 5 years) | 583 (5 RCTs) | MODERATE | POR 0.71 (0.58 to 0.87) | Acetaminophen reduces overall complication rate |

RCT – randomized controlled trial, POR – Peto odds ratio. aDowngrade a level due to some concerns or high risk of bias in trials. bDowngrade a level due to wide range of confidence interval or relatively small sample size. cDowngrade a level due to some concerns about heterogeneity (I² > 50%).

Although the present study gathered evidence more comprehensively than did the previous systematic reviews, some methodological limitations existed. First, we could not stratify the diseases underlying the pyrexia, mainly because no data that could aid in distinguishing the underlying diseases were available. Interpreting the present pooled results cautiously and considering the underlying diseases before application in clinical practice is recommended. Second, acetaminophen and ibuprofen can be administered through various strategies. However, we could not draw conclusions on the optimal medication strategy because of insufficient evidence. Future studies should discuss this further to ensure optimal treatment outcomes.

In conclusion, the present evidence provides additional information on the effects of acetaminophen and ibuprofen monotherapies in febrile children, indicating that ibuprofen might be not superior to acetaminophen even in children with mean age of approximately 5 years. Moreover, acetaminophen monotherapy may be safer than ibuprofen monotherapy, particularly in children about 5 years old. In conclusion, as the efficacy and risk of adverse events are taken into consideration comprehensively, acetaminophen monotherapy might be a better choice for antipyretic purposes in children as compared with ibuprofen monotherapy.

Acknowledgments
Ning Guo, M.D. and Nien-Yin Su, M.D. contributed equally.

Conflict of interest
The authors declare no conflict of interest.

References
1. Dixon G, Booth C, Price E, Westran R, Turner M, Klein N. Fever as nature’s engine. Part of beneficial host response? BMJ 2010; 340: c450.
2. McCance KL, Huether SE. Pathophysiology: the Biologic Basis for Disease in Adults and Children. Elsevier, St. Louis, MO 2014.
3. Bilenko N, Tessler H, Okbe R, Press I, Gorodischer R. Determinants of antipyretic misuse in children up to 5 years of age: a cross-sectional study. Clin Ther 2006; 28: 783-93.
4. Barbi E, Marzuillo P, Neri E, Naviglio S, Krauss BS. Fever in children: pearls and pitfalls. Children 2017; 4: 81.
5. Kanabar DJ. A clinical and safety review of paracetamol and ibuprofen in children. Inflammopharmacology 2017; 25: 1-9.
6. Sullivan JE, Farrar HC. Fever and antipyretic use in children. Pediatrics 2011; 127: 580-7.
7. Walson PO, Galletta G, Braden NL et al. Ibuprofen, acetaminophen, and placebo treatment of febrile children. Clin Pharmacol Ther 1989; 46: 9-17.
8. Perrott DA, Pilira T, Goodenough B, Champion GD. Efficacy and safety of acetaminophen vs ibuprofen for
treating children's pain or fever: a meta-analysis. Arch Pediatr Adolesc Med 2004; 158: 521-6.
9. Kleijnen J. Clinical safety and tolerability of ibuprofen compared with paracetamol in pediatric pain and fever. A systematic review. Minerva Pediatri 2009; 61: 757.
10. Southey ER, Soares-Weiser K, Kleijnen J. Systematic review and meta-analysis of the clinical safety and tolerability of ibuprofen compared with paracetamol in paediatric pain and fever. Curr Med Res Opin 2009; 25: 2207-22.
11. Tan E, Braithwaite I, McKinlay CJD, Dalziel SR. Comparison of acetaminophen (paracetamol) with ibuprofen for treatment of fever or pain in children younger than 2 years: a systematic review and meta-analysis. JAMA Netw Open 2020; 3: e2002398.
12. Autret E, Reboul-Marty J, Henry-Launois B, et al. Evaluation of ibuprofen versus aspirin and paracetamol on efficacy and comfort in children with fever. Eur J Clin Pharmacol 1997; 51: 367-71.
13. Figueras Nadal C, García de Miguel MJ, Gómez Campdevànol A, et al. Effectiveness and tolerability of ibuprofen-arginine versus paracetamol in children with fever of likely infectious origin. Acta Paediatr 2002; 91: 383-90.
14. Kelley MT, Watson PD, Edge JH, Cox S, Mortensen ME. Pharmacokinetics and pharmacodynamics of ibuprofen isomers and acetaminophen in febrile children. Clin Pharmacol Ther 1992; 52: 181-9.
15. Nwanyanwu OC, Ziba C, Kazemnezhad P. Paracetamol and ibuprofen for treatment of fever in Malawian children aged less than five years. Trans Royal Soc Trop Med Hyg 1999; 93: 84.
16. Ulukol B, Koşsal Y, Cin S. Assessment of the efficacy and safety of paracetamol, ibuprofen and nimesulide in children with upper respiratory tract infections. Eur J Clin Pharmacol 1999; 55: 615-8.
17. Wong A, Sibbald A, Ferrero F, et al. Antipyretic effects of dipyrone versus ibuprofen versus acetaminophen in children: results of a multinational, randomized, modified double-blind study. Clin Pediatr 2001; 40: 313-24.
18. Crook J. Fever management: evaluating the use of ibuprofen and paracetamol. Nursing Children and Young People 2010; 22: 6.
19. Higgins JP, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions. John WiIey & Sons 2019.
20. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700.
21. Marin TM, de Carvalho Indolfo N, Rocco SA, et al. Acetaminophen absorption and metabolism in an intestinal/liver microphysiological system. Chem Biol Interact 2019; 299: 59-76.
22. Shin D, Lee SJ, Ha YM, et al. Pharmacokinetic and pharmacodynamic evaluation according to absorption differences in three formulations of ibuprofen. Drug Des Devel Ther 2017; 11: 135-41.
23. Higgins JP, Sterne JAC, Savovic J, et al. A revised tool for assessing risk of bias in randomized trials. Cochrane Database Syst Rev 2016; 10 (Suppl 1): 29-31.
24. Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019; 366: l4898.
25. Ruzni N, Idris N. Modelling repeated measures data in meta-analysis: an alternative approach. Sains matematik keunggulan pemikiran. 2008, Terengganu, Malaysia Universiti Malaysia Terengganu.
43. Walson PD, Galletta G, Chomilo F, et al. Comparison of multidose ibuprofen and acetaminophen therapy in febrile children. Am J Dis Child 1992; 146: 626-32.
44. Wilson JT, Brown RD, Kearns GL, et al. Single-dose, placebo-controlled comparative study of ibuprofen and acetaminophen antipyresis in children. J Pediatr 1991; 119: 803-11.
45. Luo S, Ran M, Luo Q, et al. Alternating acetaminophen and ibuprofen versus monotherapies in improvements of distress and reducing refractory fever in febrile children: a randomized controlled trial. Paediatr Drugs 2017; 19: 479-86.
46. Government of South Australia. Children with Fever Aged 1-2 Months. South Australian Paediatric Clinical Practice Guideline. 2013: South Australia. Retrieved from https://www.sahealth.sa.gov.au/wps/wcm/connect/812ad70040d041b4972cbf4b897efc8/Fever+in+Children+aged+1-2+months_Paed_v3_1.pdf?MOD=AJPERES&CACHEID=ROOTWORKSPACE-812ad70040d041b4972cbf4b897efc8-ncGoGaw.
47. Chiappini E, Venturini E, Remaschi G, et al. 2016 Update of the Italian Pediatric Society Guidelines for management of fever in children. J Pediatr 2017; 180: 177-83.e1.
48. NSW Kids and Families. Children and Infants with Fever – Acute Management. NSW Department of Health. 2010: North Sydney NS. Retrieved from https://siloto.tips/download/children-and-infants-with-fever-acute-management.
49. WHO-GRC, WHO Guidelines Approved by the Guidelines Review Committee, in Pocket Book of Hospital Care for Children: Guidelines for the Management of Common Childhood Illnesses. World Health Organization, Geneva 2013.
50. Green R, Jeena P, Kotze S, et al. Management of acute fever in children: guideline for community healthcare providers and pharmacists. South African Med J 2013; 103: 948-54.
51. Team, N.G.U., National Institute for Health and Care Excellence: Clinical Guidelines, in Fever in under 5s: assessment and initial management. 2019. National Institute for Health and Care Excellence (UK). NICE London 2019.
52. Khalil SN, Hahn BJ, Chumpitazi CE, et al. A multicenter, randomized, open-label, active-comparator trial to determine the efficacy, safety, and pharmacokinetics of intravenous ibuprofen for treatment of fever in hospitalized pediatric patients. BMC Pediatr 2017; 17: 42.
53. Sartini I, Łebkowska-Wieruszewska B, Lisowski A, Pharmacokinetics of acetaminophen after intravenous and oral administration in fasted and fed Labrador Retriever dogs. J Vet Pharmacol Ther 2020; 44: 28-35.
54. Amar PJ, Schiff ER. Acetaminophen safety and hepatotoxicity: where do we go from here? Expert Opin Drug Saf 2007; 6: 341-55.
55. Food U. and D. Administration. FDA drug safety communication: prescription acetaminophen products to be limited to 325 mg per dosage unit; boxed warning will highlight potential for severe liver failure. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-prescription-acetaminophen-products-be-limited-325-mg-dosage-unit 2011.
56. Pantell RH, Fries JF, Vickery DM. Taking Care of Your Child: a Parent’s Illustrated Guide to Complete Medical Care. Da Capo Lifelong Books 2015.
### Appendix 1. Database and search strategy

| Database | Syntax |
|----------|--------|
| **Cochrane** | #1 fever OR pyrexia OR febrile in All Text  
#2 child OR children OR kids OR pediatric OR paediatric OR pediatrics OR paediatrics in All Text  
#3 ibuprofen in All Text  
#4 acetaminophen OR acetamol OR paracetamol in All Text  
#5 #1 AND #2 AND #3 AND #4 |
| **PubMed** | #1 fever OR pyrexia OR fever  
#2 infant OR infants OR child OR children OR kids OR pediatric OR paediatric OR pediatrics OR paediatrics in All Text  
#3 ibuprofen  
#4 acetaminophen OR acetamol OR paracetamol  
#5 #1 AND #2 AND #3 AND #4 |
| **Embase** | #1 (‘fever’/exp OR fever OR ‘body temperature elevation’ OR ‘febrile disease’ OR ‘febrile reaction’ OR ‘febrile response’ OR ‘fever’ OR ‘pyrexia’ OR ‘sweating sickness’ OR pyrexia OR febrile)  
#2 (child'/exp OR child OR ‘child’ OR children OR kids OR ‘pediatric’/exp OR pediatric OR paediatric OR ‘paediatric’/exp OR ‘paediatric’/exp OR ‘community paediatrics’ OR ‘community pediatrics’ OR ‘paediatric aspect’ OR ‘paediatric care’ OR ‘paediatric educating’ OR ‘paediatric institution’ OR ‘paediatric membership’ OR ‘paediatric perspective’ OR ‘paediatric practice’ OR ‘paediatric research’ OR ‘paediatric service’ OR ‘paediatrics’ OR ‘paediatrics department’ OR ‘pediatric aspect’ OR ‘pediatric care’ OR ‘pediatric educating’ OR ‘pediatric education’ OR ‘pediatric institution’ OR ‘pediatric internship’ OR ‘pediatric practice’ OR ‘pediatric research’ OR ‘pediatric service’ OR ‘pediatrics’ OR ‘pediatrics department’ OR ‘pediatry’ OR ‘social pediatry’ OR ‘well baby clinic’)  
#3 (‘ibuprofen’/exp OR ibuprofen OR ‘2 (4 isobutylphenyl) propionic acid’ OR ‘2 (para isobutylphenyl) propionic acid’ OR ‘2 [4 (2 methylpropyl) phenyl] propionic acid’ OR ‘afben’ OR ‘aches-n-pain’ OR ‘act-3’ OR ‘actiprofen’ OR ‘adex 200’ OR ‘adex liqui-gels’ OR ‘advil’ OR ‘advil infantil’ OR ‘advil liqui-gels’ OR ‘advil liquid caps’ OR ‘advil liquifast’ OR ‘advil liquigel’ OR ‘advil migraine liqui-gels’ OR ‘advil mono’ OR ‘advil paediatric’ OR ‘advil pediatric’ OR ‘advil ultra’ OR ‘advil ultra forte’ OR ‘advilcaps’ OR ‘advileff’ OR ‘advigel’ OR ‘advilmed’ OR ‘adviltab’ OR ‘afbelr’ OR ‘akten’ OR ‘akten forte’ OR ‘akten mobil’ OR ‘akten spezial’ OR ‘algiadin’ OR ‘algiadin retard’ OR ‘algifor’ OR ‘algofen’ OR ‘algoflex’ OR ‘algoflex forte’ OR ‘algoflex forte’ OR ‘algoflex rapid’ OR ‘aillipen’ OR ‘alpha’ (4 isobutylphenyl) propionic acid’ OR ‘aillipen express’ OR ‘am-fam 400’ OR ‘anadin (ibuprofen)’ OR ‘anadin joint pain’ OR ‘anadin liquifast’ OR ‘anadin period pain’ OR ‘anadin ultra’ OR ‘anadiv’ OR ‘anaglyl’ OR ‘anbfen’ OR ‘anco’ OR ‘andran’ OR ‘anflagen’ OR ‘antalgil’ OR ‘antilam’ OR ‘antilam forte’ OR ‘antiflam’ OR ‘ansibuprofen’ OR ‘aragel’ OR ‘astril 300’ OR ‘attribtn’ OR ‘balkaprofen’ OR ‘berlistar’ OR ‘berlistar forte’ OR ‘bestafen’ OR ‘betaprofen’ OR ‘bifen’ OR ‘bloton’ OR ‘brufen’ OR ‘brufen forte’ OR ‘brufen’ OR ‘brufen forte’ OR ‘brufen paediatric’ OR ‘brufen retard’ OR ‘brufen sr’ OR ‘brufort’ OR ‘brugesic’ OR ‘briumare (ibuprofen)’ OR ‘brumed’ OR ‘brupro’ OR ‘brupro max’ OR ‘bubufort’ OR ‘bufect’ OR ‘bufect forte’ OR ‘butohexal’ OR ‘bupogesic’ OR ‘burana’ OR ‘butacortelone’ OR ‘butifen’ OR ‘calidolor’ OR ‘calprofen’ OR ‘cap-profen’ OR ‘cenbufen’ OR ‘children’s advil’ OR ‘children’s advil-flavored’ OR ‘children’s elixsure’ OR ‘children’s ibuprofen’ OR ‘children’s motrin’ OR ‘codel’ OR ‘codel period pain’ OR ‘combiflam’ OR ‘contraneural’ OR ‘cuprofen’ OR ‘dalsy’ OR ‘dalsy forte’ OR ‘dc 7034’ OR ‘dc7034’ OR ‘dg 7034’ OR ‘dg7034’ OR ‘dibufen’ OR ‘diffutab sr 600’ OR ‘dimidon’ OR ‘dolaf powder’ OR ‘doligt’ OR ‘dolobene ibu’ OR ‘dolocyle’ OR ‘dolodolgit’ OR ‘dolofen-f’ OR ‘dolomax’ OR ‘dolormin’ OR ‘dolval’ OR ‘donjust b’ OR ‘dorival’ OR ‘drusel’ OR ‘easifon’ OR ‘ecoprofen’ OR ‘emflam’ OR ‘emflam-200’ OR ‘epobron’ OR ‘ergix douleur et fievre’ OR ‘eudorlin extra’ OR ‘eudorlin infantil’ OR ‘eudorlin migrate’ OR ‘exidol’ OR ‘expanden’ OR ‘febratic’ OR ‘febralin’ OR ‘tendrah’ OR ‘fenapirin’ OR ‘fenalgie’ OR ‘fenbit’ OR ‘flamicon’ OR ‘flarin’ OR ‘focus (drug)’ OR ‘froben dolore e febbre’ OR ‘froben dolore e inflamazione’ OR ‘galprofen’ OR ‘galprofen max’ OR ‘gelulene’ OR ‘gyno-neuralgin’ OR ‘h-loniten’ OR ‘halprin’ OR ‘haltran’ OR ‘hamagene tailleur’ OR ‘ib-100’ OR ‘ibalgan’ OR ‘ibalgan baby’ OR ‘ibalgan gel’ OR ‘ibalgan junior’ OR ‘ibalgan krem’ OR ‘ibalgan neo’ OR ‘ibalgan rapidcaps’ OR ‘ibofen’ OR ‘ibosure’ OR ‘ibu’ OR ‘iibu slow’ OR ‘ibu-4’ OR ‘ibu-6’ OR ‘ibu-8’ OR ‘ibu-slow’ OR ‘ibu-tab’ OR ‘ibu-tab 200’ OR ‘ibuberl’ OR ‘icumpol’ OR ‘ibudak’ OR ‘ibudol’ OR ‘ibudolor’ OR ‘ibuflamalid’ OR ‘ibufen’ OR ‘ibuflum’ OR ‘iibufug’ OR ‘iibus’ OR ‘iibudol forte’ OR ‘ibugesic’ OR ‘ibukern’ OR ‘ibuleve’ OR ‘iibulgan’ OR ‘iibuloid’ OR ‘ibumetin’ OR ‘ibumousse’ OR ‘ibunin’ OR ‘ibupen’ OR ‘ibupirac’ OR ‘ibuprin’ OR ‘ibuprocin’ OR ‘ibuprofen’ OR ‘ibuprofen klinge 600’ OR ‘ibuprofen potassium’ OR ‘ibutubruk’ OR ‘ibuprox’ OR ‘ibuprom’ OR ‘iburon’ OR ‘ibusol’ OR ‘ibuspray’ OR ‘ibustar’ OR ‘ibustar forte’ OR ‘ibusynth’ OR ‘ibutop’ OR ‘ibu’ OR ‘ibuxin’ OR |
Effects of acetaminophen and ibuprofen monotherapy in febrile children: a meta-analysis of randomized controlled trials
## Appendix 2. Quality assessment (RoB 2)

| Outcome | Author/year | Randomization process | Deviations from intended interventions | Missing outcome data | Measurement of the outcome | Selection of the reported result | Overall bias |
|---------|-------------|-----------------------|----------------------------------------|----------------------|---------------------------|---------------------------------|--------------|
| Afebrile | Afebrile et al. 2020 | Some concerns | Low risk | Low risk | Low risk | Low risk | Some concerns |
|         | Autret et al. 1994 | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk |
|         | Autret et al. 1997 | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk |
|         | Choi et al. 2018 | Low risk | Some concerns | Low risk | Low risk | Low risk | Some concerns |
|         | Figueras et al. 2002 | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk |
|         | Khalil et al. 2017 | Low risk | Some concerns | Low risk | Low risk | Low risk | Some concerns |
|         | Luo et al. 2017 | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk |
|         | McIntyre et al. 1996 | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk |
|         | Nwanyanwu et al. 1999 | Some concerns | Some concerns | Low risk | Low risk | Low risk | Some concerns |
|         | Seyfhashemi et al. 2007 | Low risk | Some concerns | Low risk | Low risk | Low risk | Some concerns |
|         | Ulukol et al. 1999 | Low risk | Some concerns | Low risk | Low risk | Low risk | Some concerns |
|         | Van Esch et al. 1995 | Low risk | Some concerns | Some concerns | Low risk | Low risk | Some concerns |
|         | Vauzelle et al. 1997 | Low risk | Some concerns | Low risk | Low risk | Low risk | Some concerns |
|         | Vyas et al. 2014 | Low risk | Some concerns | Low risk | Low risk | Low risk | Some concerns |
|         | Walson et al. 1989 | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk |
|         | Walson et al. 1992 | Low risk | High risk | Low risk | Low risk | Low risk | High risk |
|         | Walson et al. 1991 | Low risk | Some concerns | Low risk | Low risk | Low risk | Some concerns |
|         | Wong et al. 2001 | Low risk | Some concerns | Low risk | Low risk | Low risk | Some concerns |

### Temperature

| Outcome | Author/year | Randomization process | Deviations from intended interventions | Missing outcome data | Measurement of the outcome | Selection of the reported result | Overall bias |
|---------|-------------|-----------------------|----------------------------------------|----------------------|---------------------------|---------------------------------|--------------|
| Afebrile | Afebrile et al. 1994 | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk |
|         | Choi et al. 2009 | Low risk | Some concerns | Low risk | Low risk | Low risk | Some concerns |
|         | Figueras et al. 2002 | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk |
|         | Van Esch et al. 1995 | Low risk | Some concerns | Some concerns | Low risk | Low risk | Some concerns |
|         | Vauzelle et al. 1997 | Low risk | Some concerns | Low risk | Low risk | Low risk | Some concerns |
|         | Walson et al. 1989 | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk |
| Author/year | Outcome | Randomization process | Deviations from intended interventions | Missing outcome data | Measurement of the outcome | Selection of the reported result | Overall bias |
|-------------|---------|-----------------------|----------------------------------------|---------------------|--------------------------|--------------------------------|--------------|
| Autret et al. 1997 | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk |
| Alaje et al. 2020 | Some concerns | Low risk | Low risk | Low risk | Low risk | Low risk | Some concerns |
| Autret et al. 2007 | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk |
| Celebi et al. 2009 | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk |
| Autret et al. 2018 | Low risk | Some concerns | Low risk | Low risk | Low risk | Low risk | Some concerns |
| Figueras et al. 2002 | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk |
| Jayawardena et al. 2017 | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk |
| Khalil et al. 2017 | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk |
| Luo et al. 2017 | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk |
| McIntyre et al. 1996 | Low risk | Some concerns | Low risk | Low risk | Low risk | Low risk | Some concerns |
| Van Esch et al. 1995 | Low risk | Some concerns | Low risk | Low risk | Low risk | Low risk | Some concerns |
| Vauzelle et al. 1997 | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk |
| Vyas et al. 2014 | Low risk | Some concerns | Low risk | Low risk | Low risk | Low risk | Some concerns |
| Walson et al. 1989 | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk |
| Walson et al. 1992 | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk |
| Wilson et al. 1991 | Low risk | Some concerns | Low risk | Low risk | Low risk | Low risk | Some concerns |
| Wong et al. 2001 | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk |
### Appendix 3. Forest plot for body temperature between acetaminophen and ibuprofen monotherapies

| Time point | Study | WMD (95% CI) | N, mean (SD) | Weight (%) |
|------------|-------|--------------|--------------|------------|
| Baseline   |       |              |              |            |
|            |       | -0.17 (-0.51, 0.18) | 18, 39.1 (0.44) | 18, 39.3 (0.61) | 1.60 |
|            |       | -0.10 (-0.20, 0.00) | 116, 39.3 (0.4) | 116, 39.4 (0.4) | 6.55 |
|            |       | -0.10 (-0.22, 0.02) | 125, 38.6 (0.5) | 138, 38.7 (0.5) | 5.89 |
|            |       | -0.10 (-0.25, 0.05) | 16, 39.3 (0.3) | 30, 39.4 (0.94) | 4.89 |
|            |       | -0.10 (-0.21, 0.01) | 56, 38.9 (0.3) | 60, 39 (0.3) | 6.32 |
|            |       | -0.08 (-0.31, 0.15) | 50, 38.7 (0.58) | 50, 38.8 (0.61) | 2.94 |
|            |       | -0.08 (-0.30, 0.14) | 30, 38.6 (0.42) | 30, 38.7 (0.43) | 3.28 |
|            |       | -0.08 (-0.29, 0.13) | 30, 38.7 (0.48) | 32, 38.8 (0.36) | 3.33 |
|            |       | -0.01 (-0.10, 0.08) | 158, 39 (0.41) | 157, 39 (0.42) | 6.98 |
|            |       | -0.01 (-0.18, 0.16) | 93, 39.1 (0.56) | 94, 39.1 (0.6) | 4.43 |
|            |       | 0.00 (-0.23, 0.23) | 52, 38.6 (0.6) | 52, 38.6 (0.6) | 2.99 |
|            |       | 0.00 (-0.12, 0.12) | 151, 39.2 (0.6) | 185, 39.2 (0.6) | 5.87 |
|            |       | 0.00 (-0.08, 0.08) | 150, 38.9 (0.37) | 151, 38.9 (0.36) | 7.33 |
|            |       | 0.00 (-0.17, 0.17) | 106, 38.8 (0.6) | 86, 38.8 (0.6) | 4.31 |
|            |       | 0.00 (-0.01, 0.01) | 156, 39.1 (0.043) | 163, 39.1 (0.056) | 9.27 |
|            |       | 0.02 (-0.21, 0.25) | 77, 39 (0.76) | 77, 39 (0.72) | 2.93 |
|            |       | 0.10 (-0.32, 0.52) | 8, 39 (0.6) | 20, 38.9 (0.1) | 1.17 |
|            |       | 0.11 (-0.27, 0.49) | 36, 39.2 (0.79) | 34, 39.1 (0.83) | 1.38 |
|            |       | 0.11 (-0.05, 0.27) | 31, 39.2 (0.44) | 54, 39.1 (0.081) | 4.72 |
|            |       | 0.16 (-0.07, 0.39) | 154, 40.7 (1.01) | 155, 40.6 (1.02) | 3.06 |
|            |       | 0.18 (0.14, 0.22) | 52, 37.5 (0.12) | 90, 37.4 (0.121) | 8.73 |
|            |       | 0.20 (-0.10, 0.50) | 37, 38.9 (0.66) | 35, 38.7 (0.63) | 2.01 |
| Subtotal   |       | -0.00 (-0.05, 0.05) | 1742 | 1827 | 100.00 |
| 1 hour     |       | -0.51 (-0.66, 0.36) | 125, 37.4 (0.53) | 138, 37.9 (0.69) | 17.61 |
|            |       | -0.10 (-0.32, 0.12) | 106, 38 (0.71) | 86, 38.1 (0.6) | 17.02 |
|            |       | -0.10 (-0.28, 0.08) | 93, 38.1 (0.72) | 94, 37.9 (0.72) | 16.61 |
|            |       | 0.13 (-0.08, 0.34) | 37, 38 (0.47) | 35, 37.8 (0.69) | 15.25 |
|            |       | 0.17 (-0.10, 0.44) | 31, 38.4 (0.5) | 54, 38.3 (0.104) | 17.12 |
|            |       | 0.19 (0.01, 0.37) | 448 | 467 | 100.00 |
|            |       | -0.04 (-0.29, 0.20) | 125, 37.3 (0.62) | 138, 37.4 (0.6) | 19.67 |
|            |       | -0.15 (-0.30, 0.00) | 55, 37.9 (0.7) | 58, 37.9 (0.7) | 15.36 |
|            |       | -0.00 | 106, 37.7 (0.7) | 86, 37.9 (0.5) | 18.83 |
|            |       | 0.00 (-0.26, 0.26) | 93, 37.7 (0.78) | 94, 37.5 (0.74) | 16.95 |
|            |       | 0.00 (-0.17, 0.17) | 31, 37.9 (0.5) | 54, 37.6 (0.1) | 18.53 |
|            |       | 0.17 (-0.05, 0.39) | 29, 38 (0.915) | 30, 37.6 (0.602) | 10.65 |
|            |       | 0.35 (0.17, 0.53) | 77, 38.1 (0) | 77, 38 (0) | 0.00 |
|            |       | 0.36 (-0.04, 0.76) | 516 | 537 | 100.00 |
| (Excluded) |       | 0.10 (-0.07, 0.28) | 106, 37.5 (0.7) | 86, 37.4 (0.6) | 28.98 |
|            |       | 0.10 (-0.08, 0.28) | 55, 37.8 (0.8) | 58, 37.6 (0.8) | 20.15 |
|            |       | 0.15 (-0.16, 0.46) | 31, 37.9 (0.72) | 54, 37.4 (0.154) | 22.93 |
|            |       | 0.20 (-0.10, 0.50) | 31, 38 (1.28) | 31, 37.4 (1) | 8.49 |
|            |       | 0.52 (0.26, 0.78) | 316 | 313 | 100.00 |
|            |       | 0.57 (-0.00, 1.14) | 55, 38 (0.8) | 56, 38 (0.8) | 31.90 |
|            |       | 0.27 (0.08, 0.45) | 93, 38.1 (0.97) | 94, 37.9 (0.96) | 35.09 |
| 2 hours    |       | 0.00 (-0.30, 0.30) | 35, 38.2 (1.3) | 34, 37.8 (1.28) | 10.20 |
|            |       | 0.23 (-0.05, 0.51) | 31, 38.2 (0.5) | 54, 37.8 (0.224) | 22.81 |
|            |       | 0.41 (-0.20, 0.02) | 214 | 238 | 100.00 |
| 4 hours    |       | 0.46 (0.08, 0.84) | 0.23 (0.02, 0.43) | 46 (0.82, 0.84) | 3.05 |

Note: Weights are from random effects analysis.
Appendix 4. Forest plot for body temperature in treatment–time interaction

| Effect source          | Study                  | Study ES (95% CI) | Weight (%) |
|------------------------|------------------------|-------------------|------------|
| Treatment effects      |                        |                   |            |
| Van Esch et al. 1995   | –0.30 (–1.71, 1.10)    | 5.02              |
| Walson et al. 1989     | –0.12 (–1.51, 1.27)    | 5.16              |
| Autret et al. 1994     | –0.12 (–0.85, 0.61)    | 18.60             |
| Figueras et al. 2002   | –0.08 (–1.20, 1.04)    | 7.89              |
| Celebi et al. 2009     | 0.03 (–0.61, 0.66)     | 24.91             |
| Vauzelle et al. 1997   | 0.09 (–0.56, 0.74)     | 23.41             |
| Choi et al. 2018       | 0.23 (–0.59, 1.04)     | 15.02             |
| Subtotal (I² = 0.0%, p = 0.994) | 0.01 (–0.30, 0.33) | 100.00         |
| Time effects           |                        |                   |            |
| Choi et al. 2018       | –0.70 (–1.17, –0.23)   | 3.81              |
| Celebi et al. 2009     | –0.31 (–0.50, –0.11)   | 19.82             |
| Van Esch et al. 1995   | –0.18 (–0.47, 0.12)    | 9.28              |
| Walson et al. 1989     | –0.17 (–0.64, 0.29)    | 3.85              |
| Vauzelle et al. 1997   | –0.17 (–0.33, –0.00)   | 27.59             |
| Figueras et al. 2002   | –0.14 (–0.40, 0.12)    | 11.88             |
| Autret et al. 1994     | –0.12 (–0.30, 0.05)    | 23.77             |
| Subtotal (I² = 6.9%, p = 0.375) | –0.20 (–0.30, –0.11)   | 100.00         |
| Treatment–time interaction |                    |                   |            |
| Walson et al. 1989     | –0.08 (–0.58, 0.42)    | 5.83              |
| Van Esch et al. 1995   | –0.05 (–0.47, 0.37)    | 8.34              |
| Vauzelle et al. 1997   | –0.03 (–0.26, 0.20)    | 27.74             |
| Autret et al. 1994     | –0.03 (–0.27, 0.21)    | 25.08             |
| Celebi et al. 2009     | –0.03 (–0.31, 0.25)    | 18.83             |
| Figueras et al. 2002   | –0.03 (–0.40, 0.34)    | 10.73             |
| Choi et al. 2018       | 0.04 (–0.61, 0.69)     | 3.44              |
| Subtotal (I² = 0.0%, p = 1.000) | –0.03 (–0.15, 0.09) | 100.00         |

Note: Weights are from random effects analysis.